Inge Lefevre
Zurich, ZH, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life.
Journal: Human vaccines & immunotherapeutics
Published: October 17, 2023
Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience.
Journal: PLoS neglected tropical diseases
Published: August 03, 2023
Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination.
Journal: The Journal of infectious diseases
Published: June 01, 2023
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.
Journal: The Lancet. Global health
Published: February 22, 2023
Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue.
Journal: The American journal of tropical medicine and hygiene
Published: October 24, 2022
Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
Journal: PLoS neglected tropical diseases
Published: June 24, 2022
Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults.
Journal: Vaccine
Published: December 01, 2021
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003).
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: May 27, 2021
Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City.
Journal: Revista panamericana de salud publica = Pan American journal of public health
Published: December 18, 2020
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination.
Journal: The Journal of infectious diseases
Published: October 08, 2020
Last Updated: 09/26/2026